trending Market Intelligence /marketintelligence/en/news-insights/trending/WCfjJVemQ80TsMlX3rwHOw2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Biofrontera responds to court order in dispute with Sun Pharmaceutical's US unit

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Biofrontera responds to court order in dispute with Sun Pharmaceutical's US unit

Biofrontera AG said the recently issued court order in its ongoing litigation with a Sun Pharmaceutical Industries Ltd. unit does not stop the company from marketing and selling its products to all current and potential customers.

DUSA Pharmaceuticals Inc., a unit of Sun Pharmaceutical, had asked the U.S. District Court of Massachusetts in November for a preliminary injunction order against Biofrontera, but the request was largely rejected by the court, Biofrontera said in a Dec. 27 news release.

According to Biofrontera, the court rejected DUSA's request to collect and image computing devices from Biofrontera employees and to restrain Biofrontera from contacting certain customers.

Leverkusen, Germany-based Biofrontera said it stopped using certain documents that appear to contain DUSA information. None of the documents identified in the case contain DUSA confidential information or DUSA trade secrets. The documents identified are also not vital to its ongoing operations or strategic growth, the company said.

Biofrontera said it will continue to defend itself against DUSA's allegations that the Biofrontera companies infringed on its patents for its topical medication, Levulan Kerastick, and the specific wavelength light emitter, Blu-U Blue Light, used in photodynamic therapy.